Cargando…
Development of the neurotrophic keratopathy questionnaire: qualitative research
BACKGROUND: Neurotrophic keratopathy/keratitis (NK) is a rare disease of the cornea that can lead to anatomical loss of the eye. Little is known about the NK experience from the patients’ perspective. The objectives of this study were to examine the symptomatic experience and impacts of NK on patien...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198680/ https://www.ncbi.nlm.nih.gov/pubmed/32367451 http://dx.doi.org/10.1186/s41687-020-00192-y |
_version_ | 1783529034340106240 |
---|---|
author | Murray, Lindsey T. McCormack, Julie Grobeiu, Ioana Wiklund, Ingela Kimel, Miriam Van Nooten, Floortje |
author_facet | Murray, Lindsey T. McCormack, Julie Grobeiu, Ioana Wiklund, Ingela Kimel, Miriam Van Nooten, Floortje |
author_sort | Murray, Lindsey T. |
collection | PubMed |
description | BACKGROUND: Neurotrophic keratopathy/keratitis (NK) is a rare disease of the cornea that can lead to anatomical loss of the eye. Little is known about the NK experience from the patients’ perspective. The objectives of this study were to examine the symptomatic experience and impacts of NK on patients and assess the overall comprehension, relevance, and content validity of a new questionnaire. METHODS: This was a cross-sectional, qualitative study conducted with NK patients with varying levels of disease severity, recruited from one clinical site. One-on-one interviews using concept elicitation and cognitive interviewing techniques were conducted. RESULTS: Fourteen NK patients participated; 64.3% were female (n = 9), mean age was 65.7 ± 13.3, and 14.3% (n = 2), 21.4% (n = 3), and 64.3% (n = 9) were classified as Mackie stage I, stage II, or stage III, respectively. Participants reported 24 concepts, including: redness (n = 12, 86%), sensitivity to light (n = 11, 79%), general discomfort (n = 9, 64%), dry eye (n = 9, 64%), reduced visual acuity (n = 9, 64%), blurred vision (n = 8, 57%), and eye fatigue (n = 8, 57%). No new concepts were reported after the 13th interview. The most frequently reported impacts included frustration (n = 10, 71%), driving impairment (n = 8, 57%), reading impairment (n = 7, 50%), difficulty watching television (n = 7, 50%), and concern with potentially losing their eyesight due to NK (n = 6, 43%). Participants provided positive feedback on the draft NK Questionnaire (NKQ) and felt that it was comprehensive and relevant to their experience with NK. Additionally, the recall period, instructions, item concepts, and response options were well-understood by participants. Minor revisions were made to the tool for consistency (i.e., the timeframe “in the past 7 days” was added to items 12–14); item 14 was modified to include “how often”; examples were added to item 9. CONCLUSIONS: The results of the concept elicitation portion of the qualitative study support the content validity of the draft NKQ. The clinically significant concepts identified in the literature and raised during concept elicitation are included as items in the questionnaire. Further assessment of the psychometric properties should be conducted in support of this new tool to measure the effect of new treatments on symptoms and impacts associated with NK. |
format | Online Article Text |
id | pubmed-7198680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-71986802020-05-06 Development of the neurotrophic keratopathy questionnaire: qualitative research Murray, Lindsey T. McCormack, Julie Grobeiu, Ioana Wiklund, Ingela Kimel, Miriam Van Nooten, Floortje J Patient Rep Outcomes Research BACKGROUND: Neurotrophic keratopathy/keratitis (NK) is a rare disease of the cornea that can lead to anatomical loss of the eye. Little is known about the NK experience from the patients’ perspective. The objectives of this study were to examine the symptomatic experience and impacts of NK on patients and assess the overall comprehension, relevance, and content validity of a new questionnaire. METHODS: This was a cross-sectional, qualitative study conducted with NK patients with varying levels of disease severity, recruited from one clinical site. One-on-one interviews using concept elicitation and cognitive interviewing techniques were conducted. RESULTS: Fourteen NK patients participated; 64.3% were female (n = 9), mean age was 65.7 ± 13.3, and 14.3% (n = 2), 21.4% (n = 3), and 64.3% (n = 9) were classified as Mackie stage I, stage II, or stage III, respectively. Participants reported 24 concepts, including: redness (n = 12, 86%), sensitivity to light (n = 11, 79%), general discomfort (n = 9, 64%), dry eye (n = 9, 64%), reduced visual acuity (n = 9, 64%), blurred vision (n = 8, 57%), and eye fatigue (n = 8, 57%). No new concepts were reported after the 13th interview. The most frequently reported impacts included frustration (n = 10, 71%), driving impairment (n = 8, 57%), reading impairment (n = 7, 50%), difficulty watching television (n = 7, 50%), and concern with potentially losing their eyesight due to NK (n = 6, 43%). Participants provided positive feedback on the draft NK Questionnaire (NKQ) and felt that it was comprehensive and relevant to their experience with NK. Additionally, the recall period, instructions, item concepts, and response options were well-understood by participants. Minor revisions were made to the tool for consistency (i.e., the timeframe “in the past 7 days” was added to items 12–14); item 14 was modified to include “how often”; examples were added to item 9. CONCLUSIONS: The results of the concept elicitation portion of the qualitative study support the content validity of the draft NKQ. The clinically significant concepts identified in the literature and raised during concept elicitation are included as items in the questionnaire. Further assessment of the psychometric properties should be conducted in support of this new tool to measure the effect of new treatments on symptoms and impacts associated with NK. Springer International Publishing 2020-05-04 /pmc/articles/PMC7198680/ /pubmed/32367451 http://dx.doi.org/10.1186/s41687-020-00192-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Murray, Lindsey T. McCormack, Julie Grobeiu, Ioana Wiklund, Ingela Kimel, Miriam Van Nooten, Floortje Development of the neurotrophic keratopathy questionnaire: qualitative research |
title | Development of the neurotrophic keratopathy questionnaire: qualitative research |
title_full | Development of the neurotrophic keratopathy questionnaire: qualitative research |
title_fullStr | Development of the neurotrophic keratopathy questionnaire: qualitative research |
title_full_unstemmed | Development of the neurotrophic keratopathy questionnaire: qualitative research |
title_short | Development of the neurotrophic keratopathy questionnaire: qualitative research |
title_sort | development of the neurotrophic keratopathy questionnaire: qualitative research |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198680/ https://www.ncbi.nlm.nih.gov/pubmed/32367451 http://dx.doi.org/10.1186/s41687-020-00192-y |
work_keys_str_mv | AT murraylindseyt developmentoftheneurotrophickeratopathyquestionnairequalitativeresearch AT mccormackjulie developmentoftheneurotrophickeratopathyquestionnairequalitativeresearch AT grobeiuioana developmentoftheneurotrophickeratopathyquestionnairequalitativeresearch AT wiklundingela developmentoftheneurotrophickeratopathyquestionnairequalitativeresearch AT kimelmiriam developmentoftheneurotrophickeratopathyquestionnairequalitativeresearch AT vannootenfloortje developmentoftheneurotrophickeratopathyquestionnairequalitativeresearch |